FDA Approves Nivolumab for Patients With BRAF V600 Wild-Type Advanced Melanoma


11 ottobre 2015 - 09:01Rassegna stampa


The US Food and Drug Administration (FDA) has granted accelerated approval to nivolumab (Opdivo) in combination with ipilimumab for the treatment of patients with BRAF V600 wild-type, unresectable or metastatic melanoma.

The approval was based on demonstration of an increase in the objective response rate (ORR), prolonged response durations, and improvement in progression-free survival (PFS) in an international, multicentre, double-blind, randomised, 2-arm, active-controlled trial in patients who were previously untreated for unresectable or metastatic, BRAF V600 wild-type melanoma.

The study randomised (2:1) 142 patients to receive nivolumab plus ipilimumab (n = 95) or ipilimumab plus placebo (n = 47). Randomisation was stratified by BRAF V600 mutation status based on an FDA-approved test.

Patients in the nivolumab plus ipilimumab arm received nivolumab 1 mg/kg and ipilimumab 3 mg/kg intravenously every 3 weeks for 4 doses, then nivolumab 3 mg/kg every 2 weeks until disease progression or unacceptable toxicity. Patients in the ipilimumab arm received ipilimumab 3 mg/kg and nivolumab-matched placebo intravenously every 3 weeks for 4 doses followed by placebo. At the time of disease progression, patients on the ipilimumab arm were offered nivolumab 3 mg/kg every 2 weeks.

The trial demonstrated a significant improvement in ORR. The ORR was 60% in the nivolumab plus ipilimumab group and 11% in the ipilimumab group -- an improvement in ORR of 49% (P < .001).

Of the 43 patients with an objective response in the nivolumab plus ipilimumab group, 9 patients (21%) with response duration ranging from 3 to 7 months have progressed after response, died, or received subsequent therapy.

The remaining 34 patients (79%) had ongoing responses at the time of final analysis; in 14 patients the duration of ongoing responses is at least 6 months but less than 9 months and in 20 patients the duration of ongoing responses is at least 9 months.

In addition, there was a significant improvement in PFS for the combination group compared with the ipilimumab group (hazard ratio [HR], 0.40; P < .002), with an estimated median PFS of 8.9 and 4.7 months in the nivolumab plus ipilimumab and ipilimumab groups, respectively.

Among the 140 patients with BRAF V600 wild-type or mutation-positive melanoma who received at least 1 dose of nivolumab or ipilimumab, serious adverse reactions (62% vs 39%), adverse reactions leading to permanent discontinuation (43% vs 11%) or dose delay (47% vs 22%), and grade 3 or 4 adverse reactions (69% vs 43%) all occurred more frequently in patients receiving the combination (n = 94) compared with those receiving single-agent ipilimumab (n = 46).

The most frequent serious adverse reactions in patients receiving the combination were colitis (17%), diarrhoea (9%), pyrexia (6%), and pneumonitis (5%). Clinically significant immune-mediated adverse reactions included pneumonitis, hepatitis, endocrinopathies, nephritis/renal dysfunction, and rash.

Common adverse reactions (?20%) in patients receiving nivolumab plus ipilimumab were rash, pruritus, headache, vomiting, and colitis. The most frequent grade 3 and 4 laboratory abnormalities occurring in at least 5% of patients receiving the combination were increased ALT, increased AST, increased lipase, increased amylase, hyponatremia, and lymphopenia.

When used in combination with ipilimumab, the recommended dose and schedule is nivolumab 1 mg/kg administered as an intravenous infusion over 60 minutes, followed by ipilimumab on the same day, every 3 weeks for 4 doses. The recommended subsequent dose of nivolumab, as a single agent, is 3 mg/kg as an intravenous infusion over 60 minutes every 2 weeks until disease progression or unacceptable toxicity.

Inserito da segreteria SIDeMaST

La rassegna stampa contiene articoli di interesse dermatologico tratti da testate nazionali e non intende fornire una revisione critica né essere una fonte di notizie scientificamente validate. Si accettano (e sono bene graditi) commenti da parte dei soci esperti nel settore.

Lascia un commento sul sito e rispondi all'autore

I commenti sono soggetti a moderazione: non saranno pubblicati immediatamente ma dovranno essere approvati dalla segreteria.

Eventi SIDeMaST

Stato iscrizione